Axon Enterprise, Inc. (NASDAQ:AXON) Shares Bought by Centaurus Financial Inc.

Centaurus Financial Inc. lifted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 43.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,517 shares of the biotechnology company's stock after purchasing an additional 1,989 shares during the period. Centaurus Financial Inc.'s holdings in Axon Enterprise were worth $3,873,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AXON. Perigon Wealth Management LLC bought a new stake in shares of Axon Enterprise in the fourth quarter worth $488,000. Geneos Wealth Management Inc. increased its stake in Axon Enterprise by 630.0% during the fourth quarter. Geneos Wealth Management Inc. now owns 1,847 shares of the biotechnology company's stock valued at $1,098,000 after purchasing an additional 1,594 shares during the last quarter. Chicago Capital LLC increased its stake in Axon Enterprise by 8.2% during the fourth quarter. Chicago Capital LLC now owns 23,358 shares of the biotechnology company's stock valued at $13,882,000 after purchasing an additional 1,775 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in Axon Enterprise during the fourth quarter valued at $525,000. Finally, Savant Capital LLC increased its stake in Axon Enterprise by 5.7% during the fourth quarter. Savant Capital LLC now owns 1,080 shares of the biotechnology company's stock valued at $642,000 after purchasing an additional 58 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the sale, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Brittany Bagley sold 3,400 shares of the company's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the sale, the chief financial officer now directly owns 131,833 shares of the company's stock, valued at $92,283,100. The trade was a 2.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,969 shares of company stock valued at $23,127,314 over the last 90 days. 5.70% of the stock is currently owned by company insiders.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded up $13.34 during trading on Friday, hitting $743.63. 1,121,061 shares of the stock were exchanged, compared to its average volume of 732,673. The stock has a market cap of $57.89 billion, a PE ratio of 192.15, a P/E/G ratio of 5.17 and a beta of 1.24. The stock's fifty day moving average is $620.57 and its 200 day moving average is $610.60. Axon Enterprise, Inc. has a 12 month low of $273.52 and a 12 month high of $755.05. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company's quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 earnings per share. As a group, sell-side analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on AXON shares. Needham & Company LLC boosted their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Barclays boosted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Finally, Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $652.73.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.